Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses

English version České info

Most monoclonal antibodies (mAbs) to the influenza A virus hemagglutinin (HA) head domain exhibit very limited breadth of inhibitory activity due to antigenic drift in field strains. However, mAb 1F1, isolated from a 1918 influenza pandemic survivor, inhibits select human H1 viruses (1918, 1943, 1947, and 1977 isolates). The crystal structure of 1F1 in complex with the 1918 HA shows that 1F1 contacts residues that are classically defined as belonging to three distinct antigenic sites, Sa, Sb and Ca₂. The 1F1 heavy chain also reaches into the receptor binding site (RBS) and interacts with residues that contact sialoglycan receptors and determine HA receptor specificity. The 1F1 epitope is remarkably similar to the previously described murine HC63 H3 epitope, despite significant sequence differences between H1 and H3 HAs. Both antibodies potently inhibit receptor binding, but only HC63 can block the pH-induced conformational changes in HA that drive membrane fusion. Contacts within the RBS suggested that 1F1 may be sensitive to changes that alter HA receptor binding activity. Affinity assays confirmed that sequence changes that switch the HA to avian receptor specificity affect binding of 1F1 and a mAb possessing a closely related heavy chain, 1I20. To characterize 1F1 cross-reactivity, additional escape mutant selection and site-directed mutagenesis were performed. Residues 190 and 227 in the 1F1 epitope were found to be critical for 1F1 reactivity towards 1918, 1943 and 1977 HAs, as well as for 1I20 reactivity towards the 1918 HA. Therefore, 1F1 heavy-chain interactions with conserved RBS residues likely contribute to its ability to inhibit divergent HAs.

Vyšlo v časopise: Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses. PLoS Pathog 8(12): e32767. doi:10.1371/journal.ppat.1003067
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003067

Souhrn

Zdroje

1. EkiertDC, BhabhaG, ElsligerMA, FriesenRH, JongeneelenM, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246–251.

2. KashyapAK, SteelJ, OnerAF, DillonMA, SwaleRE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105: 5986–5991.

3. OkunoY, IsegawaY, SasaoF, UedaS (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2552–2558.

4. SuiJ, HwangWC, PerezS, WeiG, AirdD, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265–273.

5. ThrosbyM, van den BrinkE, JongeneelenM, PoonLL, AlardP, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.

6. WrammertJ, KoutsonanosD, LiGM, EdupugantiS, SuiJ, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181–193.

7. YoshidaR, IgarashiM, OzakiH, KishidaN, TomabechiD, et al. (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 5: e1000350.

8. OhshimaN, IbaY, Kubota-KoketsuR, AsanoY, OkunoY, et al. (2011) Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol 85: 11048–11057.

9. WhittleJR, ZhangR, KhuranaS, KingLR, ManischewitzJ, et al. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108: 14216–14221.

10. KrauseJC, TsibaneT, TumpeyTM, HuffmanCJ, BaslerCF, et al. (2011) A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85: 10905–10908.

11. KrauseJC, TsibaneT, TumpeyTM, HuffmanCJ, AlbrechtR, et al. (2012) Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol 86: 6334–6340.

12. DreyfusC, LaursenNS, KwaksT, ZuijdgeestD, KhayatR, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343–1348.

13. LeePS, YoshidaR, EkiertDC, SakaiN, SuzukiY, et al. (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor-binding site enhanced by avidity. Proc Natl Acad Sci U S A 109: 17040–17045.

14. EkiertDC, KashyapAK, SteelJ, RubrumA, BhabhaG, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526–532.

15. CatonAJ, BrownleeGG, YewdellJW, GerhardW (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417–427.

16. BrownleeGG, FodorE (2001) The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos Trans R Soc Lond B Biol Sci 356: 1871–1876.

17. GerhardW, YewdellJ, FrankelM, WebsterR (1981) Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290: 713–717.

18. YuX, TsibaneT, McGrawPA, HouseFS, KeeferCJ, et al. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455: 532–536.

19. LefrancMP, GiudicelliV, GinestouxC, Jabado-MichaloudJ, FolchG, et al. (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37: D1006–1012.

20. GamblinS, HaireL, RussellR, StevensD, XiaoB, et al. (2004) The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303: 1838–1842.

21. StevensJ, CorperAL, BaslerCF, TaubenbergerJK, PaleseP, et al. (2004) Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303: 1866–1870.

22. VerdinoP, WitherdenDA, HavranWL, WilsonIA (2010) The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science 329: 1210–1214.

23. ColmanPM, TulipWR, VargheseJN, TullochPA, BakerAT, et al. (1989) Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos Trans R Soc Lond B Biol Sci 323: 511–518.

24. GlaserL, StevensJ, ZamarinD, WilsonIA, Garcia-SastreA, et al. (2005) A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol 79: 11533–11536.

25. StevensJ, BlixtO, GlaserL, TaubenbergerJK, PaleseP, et al. (2006) Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 355: 1143–1155.

26. ConnorRJ, KawaokaY, WebsterRG, PaulsonJC (1994) Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205: 17–23.

27. NaeveCW, HinshawVS, WebsterRG (1984) Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus. J Virol 51: 567–569.

28. DanielsPS, JeffriesS, YatesP, SchildGC, RogersGN, et al. (1987) The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. The EMBO Journal 6: 1459–1465.

29. Barbey-MartinC, GigantB, BizebardT, CalderLJ, WhartonSA, et al. (2002) An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 294: 70–74.

30. KrauseJC, TsibaneT, TumpeyTM, HuffmanCJ, BrineyBS, et al. (2011) Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. Journal of Immunology 187: 3704–3711.

31. XuR, EkiertD, KrauseJ, HaiR, CroweJJ, et al. (2010) Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328: 357–360.

32. KembleGW, BodianDL, RoseJ, WilsonIA, WhiteJM (1992) Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin. Journal of Virology 66: 4940–4950.

33. HirstGK (1952) Strain-specific elements in influenza antigens. J Exp Med 96: 589–603.

34. WilsonIA, SkehelJJ, WileyDC (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289: 366–373.

35. McCoyAJ, Grosse-KunstleveRW, AdamsPD, WinnMD, StoroniLC, et al. (2007) Phaser crystallographic software. Journal of Applied Crystallography 40: 658–674.

36. AdamsPD, AfoninePV, BunkocziG, ChenVB, DavisIW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica Section D, Biological Crystallography 66: 213–221.

37. EmsleyP, LohkampB, ScottWG, CowtanK (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486–501.

38. ChenBJ, LeserGP, MoritaE, LambRA (2007) Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81: 7111–7123.

39. Kendal AP, Skehel JJ, Pereira MS (1982) World Health Organization Collaborating Centers for Reference and Research on Influenza: concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: World Health Organization Collaborating Centers for Reference and Research in Influenza, Centers for Disease Control. B17–B35 p.

40. YewdellJW, WebsterRG, GerhardWU (1979) Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279: 246–248.

41. KrauseJC, TumpeyTM, HuffmanCJ, McGrawPA, PearceMB, et al. (2010) Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 84: 3127–3130.

42. SheriffS, HendricksonWA, SmithJL (1987) Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution. Journal of Molecular Biology 197: 273–296.